Interaction of CYP2B6 Genotype and Efavirenz With Methadone and Tizanidine PK
Recruiting
Early Phase 1
Interventional Study
Drug-Drug Interaction
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
At a Glance
- Age
- 18 – 65
- Sex
- Any
- Trial phase
- Early Phase 1
- Study type
- Interventional
- Purpose
- Basic Science
- Participants needed
- 60 (estimated)
- Sponsor
- Indiana University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The main goal of this clinical study is to test how CYP2B6 genetic variations and efavirenz (cornerstone in HIV-1 therapy) dictate the disposition (PK) of CYP2B6 substrate (methadone) and PK and effect (PD) of CYP1A2 substrate (tizanidine). Specifically, the investigators will test whether efavirenz produces CYP2B6 genotype dependent unanticipated DDIs with CYP2B6 (methadone) and CYP1A2 (tizanidin…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Subjects will be included in the study if participants:
* are male and female (approximately 1:1) volunteers between the age of 18 and 65 years old
* are judged healthy without any significant medical condition as determined by and decided from a pre-enrollment screening sessio…
Contacts